Physician profile
Charles E Howard
NPI 1659759157
$12,915.50
in general payments reported to CMS, 2019-2025
25 companies · $81.32 in 2025
The $81.32 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,681 · 2020: $2,188 · 2021: $772 · 2022: $3,504 · 2023: $2,019 · 2024: $670 · 2025: $81.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,394 · Food and Beverage: $1,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,394.16 |
| Food and Beverage | $1,376.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,757.32 | 2019-2024 | Tacticath Ablation Catheter, Sensor Enabled, Na, Viewmate |
| Abiomed | $1,810.95 | 2022-2023 | Impella |
| Boston Scientific Corporation | $1,401.15 | 2019-2025 | Avvigo Guidance System, Watchman Access System |
| Edwards Lifesciences Corporation | $815.48 | 2021-2024 | Sapien 3 Ultra Resilia |
| Cardiovascular Systems INC. | $255.35 | 2019-2021 | |
| Cvrx, INC. | $92.34 | 2023-2024 | Barostim Neo System |
| Medtronic, INC. | $89.36 | 2024 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan, Linq II |
| Astrazeneca Pharmaceuticals Lp | $86.08 | 2019-2020 | |
| Amgen INC. | $85.63 | 2022-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $71.22 | 2024-2025 | |
| Novo Nordisk INC | $66.54 | 2023 | Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.05 | 2023-2024 | Lifevest |
| Innovation Technologies INC | $49.80 | 2022 | |
| Heartflow, INC. | $48.67 | 2023 | Ffrct |
| Janssen Pharmaceuticals, INC | $37.05 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.98 | 2024 | Jardiance |
| W. L. Gore & Associates, INC. | $22.87 | 2024 | Gore Cardioform Septal Occluder |
| Lexicon Pharmaceuticals, INC. | $22.39 | 2023 | Inpefa |
| Vital Connect, INC | $17.64 | 2023 | Vitalpatch Rtm |
| Irhythm Technologies, INC. | $17.47 | 2024 | Zio Monitor, Zio Xt Patch |
| Pfizer INC. | $15.79 | 2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $15.61 | 2023 | Arcalyst |
| Chiesi USA, INC. | $15.14 | 2022 | |
| Lantheus Medical Imaging, INC. | $14.88 | 2020 | |
| Ge Healthcare | $14.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.